Daily image-guided radiotherapy, when compared to weekly control, decreases the risk of recurrence and rectal toxicity, but is associated with an increased risk of second cancer, according to study results presented at the 2018 Genitourinary Cancers Symposium.
During a session at the 2018 Genitourinary Cancers Symposium, study results showed that daily image-guided radiotherapy (IGRT), when compared to weekly control, decreases the risk of recurrence and rectal toxicity, but is associated with an increased risk of second cancer.
“While there is a strong rational for prostate cancer IGRT, optimal frequency of the control is not clearly identified,” said Renaud de Crevoisier, MD, PhD, professor, University of Rennes, radiation-oncologist, Regional Cancer Center. “It may be possible to correct only for the systematic error by doing a control on day 1, 2, 3, and weekly, or it may be necessary to correct for systematic and random error by doing a daily control.”
The phase 3 randomized trial comprised of 2 steps: the first was a feasibility step for the first 5 patients. Then, 470 patients from 21 centers were randomized 1:1 between 2 arms: weekly control or daily control between June 2007 and November 2012.
According to Crevoisier, the hypothesis was to detect a minimum of a 12% difference in 5-year disease-free survival (DFS) between the groups. The patients were stratified between center, prognostic group, total dose, and androgen deprivation therapy. The median follow-up was 4.1 years. Secondary outcomes included overall survival (OS) and toxicity. Post-hoc analyses included biochemical progression-free interval, clinical progression-free interval and second cancer-free interval.
For toxicity, acute rectal bleeding greater than grade 1 decreased significantly in the daily control group (6% versus 11%). Rectal toxicity, BPFI, and clinical recurrence also decreased significantly in the daily control group.
Surprisingly, OS decreased in the daily control group, said Crevoisier. The risk of death increasedby a factor of 2. Looking at second cancer incidence in the post-hoc analysis, the risk of second incidence was also multiplied by 2 in the daily control group.
“Compared to weekly control, by improving targeting, daily control in prostate cancer IGRT significantly decreases the risks of recurrence and rectal toxicity but is associated with an increased risk of second cancer,” concluded Crevoisier. “Longer follow-up is however clearly needed to assess the rate of radiation-associated malignancies.”
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More